Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
Provided By PR Newswire
Last update: May 14, 2025
Processed 3,034 EsoGuard® tests and recognized revenue of $0.8 million in 1Q25
Secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash
Read more at prnewswire.comNASDAQ:PAVM (8/25/2025, 2:41:37 PM)
0.48
+0.01 (+2.13%)
NASDAQ:LUCD (8/25/2025, 2:47:44 PM)
1.16
+0.06 (+5.45%)
Find more stocks in the Stock Screener
